newsfilter
← Latest News
PR Newswire·

Liminal BioSciences Reports Third Quarter 2022 Financial Results and Business Highlights

$40.8M of cash and cash equivalents at September 30, 2022 Discontinuation of fezagepras developmentTermination of legacy CDMO agreement for cash savings of $33.1 millionNet loss from continuing operations of $4.5 million